The 4-quinolone antibiotics: past, present, and future (Q39314610)

10 September 2017

1 reference

title

The 4-quinolone antibiotics: past, present, and future (English)

1 reference

10 September 2017

0 references

Stein GE

1 reference

10 September 2017

language of work or name

English

0 references

publication date

1 January 1988

1 reference

10 September 2017

1 reference

10 September 2017

1 reference

10 September 2017

1 reference

10 September 2017

page(s)

301-314

1 reference

Norfloxacin: clinical pharmacology and clinical use.

10 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1988.TB04088.X

Ciprofloxacin: chemistry, mechanism of action, resistance, antimicrobial spectrum, pharmacokinetics, clinical trials, and adverse reactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1988.TB04088.X

Differences in susceptibility to quinolones of outer membrane mutants of Salmonella typhimurium and Escherichia coli

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1988.TB04088.X

Synthesis and antibacterial activities of optically active ofloxacin

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1988.TB04088.X

DNA gyrase: an enzyme that introduces superhelical turns into DNA

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1988.TB04088.X

DNA Gyrase and the Supercoiling of DNA

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1988.TB04088.X

Mechanism of inhibition of DNA gyrase by analogues of nalidixic acid: the target of the drugs is DNA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1988.TB04088.X

Inhibition of Micrococcus luteus DNA gyrase by norfloxacin and 10 other quinolone carboxylic acids

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1988.TB04088.X

Association between early inhibition of DNA synthesis and the MICs and MBCs of carboxyquinolone antimicrobial agents for wild-type and mutant [gyrA nfxB(ompF) acrA] Escherichia coli K-12

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1988.TB04088.X

Nalidixic acid resistance: A second genetic character involved in DNA gyrase activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1988.TB04088.X

Endogenous active efflux of norfloxacin in susceptible Escherichia coli

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1988.TB04088.X

Genetic and biochemical characterization of norfloxacin resistance in Escherichia coli

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1988.TB04088.X

Plasmid-mediated resistance to nalidixic acid in Shigella dysenteriae type 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1988.TB04088.X

In vitro and in vivo activity of ciprofloxacin against enterococci isolated from patients with infective endocarditis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1988.TB04088.X

In vitro evaluation of A-56619 (difloxacin) and A-56620: new aryl-fluoroquinolones

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1988.TB04088.X

Antibacterial activity of norfloxacin

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1988.TB04088.X

In vitro activity of Ro 23-6240, a new fluorinated 4-quinolone

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1988.TB04088.X

Comparative in-vitro activity of five fluoroquinolones against mycobacteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1988.TB04088.X

In vitro susceptibility of Rickettsia conorii to ciprofloxacin as determined by suppressing lethality in chicken embryos and by plaque assay

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1988.TB04088.X

Activity of fluoroquinolone antibiotics against Plasmodium falciparum in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1988.TB04088.X

Mode of action, and in vitro and in vivo activities of the fluoroquinolones

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1988.TB04088.X

Ciprofloxacin, a quinolone carboxylic acid compound active against aerobic and anaerobic bacteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1988.TB04088.X

Resistance occurring after fluoroquinolone therapy of experimental Pseudomonas aeruginosa peritonitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1988.TB04088.X

The emergence of resistance to ciprofloxacin during treatment of experimental Staphylococcus aureus endocarditis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1988.TB04088.X

Selection of multiple antibiotic resistance by quinolones, beta-lactams, and aminoglycosides with special reference to cross-resistance between unrelated drug classes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1988.TB04088.X

Bactericidal activity and killing rate of serum in volunteers receiving pefloxacin alone or in combination with ceftazidime, piperacillin or mezlocillin against Pseudomonas aeruginosa.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1988.TB04088.X

Sub-MICs of cefuroxime and ciprofloxacin influence interaction of complement and immunoglobulins with Klebsiella pneumoniae

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1988.TB04088.X

4-Quinolone drugs affect cell cycle progression and function of human lymphocytes in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1988.TB04088.X

Recovery of norfloxacin in feces after administration of a single oral dose to human volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1988.TB04088.X

Effect of food on enoxacin absorption

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1988.TB04088.X

Effects of antacids and dialysate dwell times on multiple-dose pharmacokinetics of oral ciprofloxacin in patients on continuous ambulatory peritoneal dialysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1988.TB04088.X

Clinical efficacy and levels of ciprofloxacin in tissue in patients with soft tissue infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1988.TB04088.X

Bone penetration of enoxacin in patients with and without osteomyelitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1988.TB04088.X

Pharmacokinetics and sputum penetration of ciprofloxacin in patients with cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1988.TB04088.X

Norfloxacin penetration into human renal and prostatic tissues

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1988.TB04088.X

Penetration of pefloxacin into cerebrospinal fluid of patients with meningitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1988.TB04088.X

Pefloxacin concentrations in human aqueous humour and lens

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1988.TB04088.X

Absorption, distribution, metabolic fate, and elimination of pefloxacin mesylate in mice, rats, dogs, monkeys, and humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1988.TB04088.X

Effect of multiple dose oral ciprofloxacin on the pharmacokinetics of theophylline and indocyanine green

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1988.TB04088.X

The influence of quinolone derivatives on theophylline clearance

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1988.TB04088.X

The effect of ciprofloxacin on antipyrine metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1988.TB04088.X

Effect of dose on serum pharmacokinetics of intravenous ciprofloxacin with identification and characterization of extravascular compartments using noncompartmental and compartmental pharmacokinetic models

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1988.TB04088.X

Changes in the pharmacokinetics of ciprofloxacin and fecal flora during administration of a 7-day course to human volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1988.TB04088.X

Single- and multiple-dose pharmacokinetics of fleroxacin, a trifluorinated quinolone, in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1988.TB04088.X

Norfloxacin disposition after sequentially increasing oral doses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1988.TB04088.X

Ofloxacin pharmacokinetics in renal failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1988.TB04088.X

No cytogenetic effects of quinolone treatment in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1988.TB04088.X

Effect of 4-quinolones and novobiocin on calf thymus DNA polymerase alpha primase complex, topoisomerases I and II, and growth of mammalian lymphoblasts

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1988.TB04088.X

Effects of ciprofloxacin on eucaryotic pyrimidine nucleotide biosynthesis and cell growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1988.TB04088.X

Nalidixic acid in children: retrospective matched controlled study for cartilage toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1988.TB04088.X

Inhibitory effect of cephalosporins on gamma-aminobutyric acid receptor binding in rat synaptic membranes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1988.TB04088.X

Inhibitory effects of quinolone antibacterial agents on gamma-aminobutyric acid binding to receptor sites in rat brain membranes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1988.TB04088.X

Ciprofloxacin and allergic interstitial nephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1988.TB04088.X

Synergistic nephrotoxicity due to ciprofloxacin and cyclosporine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1988.TB04088.X

Nalidixic acid and bacterial chromosome replication

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1988.TB04088.X

10.1002/J.1875-9114.1988.TB04088.X

21 January 2018

Identifiers

DOI

1 reference

10 September 2017

1 reference